Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. Wang E, et al. Among authors: montoya s. N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110. N Engl J Med. 2022. PMID: 35196427 Free PMC article.
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T, Mukerji R, Reddy PJ, Powers J, Sanchez Garcia de Los Rios M, Ye J, Barrientos Risso C, Tsai D, Pardo G, Notti RQ, Pardo A, Affer M, Nawaratne V, Totiger TM, Pena-Velasquez C, Rhodes JM, Zelenetz AD, Alencar A, Roeker LE, Mehta S, Garippa R, Linley A, Soni RK, Skånland SS, Brown RJ, Mato AR, Hansen GM, Abdel-Wahab O, Taylor J. Montoya S, et al. Science. 2024 Feb 2;383(6682):eadi5798. doi: 10.1126/science.adi5798. Epub 2024 Feb 2. Science. 2024. PMID: 38301010
Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Totiger TM, Chaudhry S, Musi E, Afaghani J, Montoya S, Owusu-Ansah F, Lee S, Schwartz G, Klimek V, Taylor J. Totiger TM, et al. Among authors: montoya s. J Cell Mol Med. 2023 Feb;27(4):587-590. doi: 10.1111/jcmm.17667. Epub 2023 Feb 1. J Cell Mol Med. 2023. PMID: 36722323 Free PMC article.
Targeted Therapies in Cancer: To Be or Not to Be, Selective.
Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Montoya S, et al. Biomedicines. 2021 Nov 1;9(11):1591. doi: 10.3390/biomedicines9111591. Biomedicines. 2021. PMID: 34829820 Free PMC article. Review.
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).
Nguyen N, Chaudhry S, Totiger TM, Diaz R, Roberts E, Montoya S, Pardo G, Pardo A, Afaghani J, Affer M, Jahn J, Bradley T, Maura F, Kazandjian D, Bilbao D, Chapman J, Landgren O, Hoffman J, Taylor J. Nguyen N, et al. Among authors: montoya s. NPJ Precis Oncol. 2022 Oct 19;6(1):73. doi: 10.1038/s41698-022-00315-2. NPJ Precis Oncol. 2022. PMID: 36261486 Free PMC article.